User Name Password

back to homepage

KleenAir Systems (KSI.L) - results
KSI.L
Comment by Objective Capital , Apr 01, 2008
Questions? Contact our analyst

KleenAir has announced its results for the full year ending 30 September 2007. Sales in the year were £35,102 (9 months to 30 September 2006: Nil) and group costs, which were primarily associated with management infrastructure and the costs of implementing the applications engineering and administrative facility in Ross-on-Wye, amounted to £866,817 (£710,281). The loss for the year was £825,003 (£699,262).

Other items of note were, a cash outflow before financing of £871.7k (£690.8K) and a net cash outflow after financing of £474.6k (inflow of £437k) and a year end cash balance of £9.2k (£483.8K).

Objective's view:

2007 was very much a year of preparation for KleenAir, hence the almost negligible sales. Following a disappointment with its patented Noxmaster technology and an initial setback with Dinex, management identified the London Low Emission Zone (LEZ) as its target market, secured a suitable filter and applied for certification from TfL.

Although the LEZ was signed into force in May 2007 KleenAir did not receive certification until September, too late to generate any meaningful sales in the 2006/07 financial year.

Of more interest to investors are the subsequent events some of which are mentioned in the RNS announcement.

The first stage of LEZ compliance was that HGVs over 12 tonnes were required to be retrofitted with filters to make them compliant with Euro III particulate emission standards. After intense lobbying from the engine manufacturers TfL granted various exemptions which reduced the estimated market size for vehicles over 12 tonnes by more than 50%. The resulting confusion also caused many operators to delay compliance work.

KleenAir has now begun shipments and is ramping up production for the next phase, which is for HGVs between 3.5 and 12 tonnes and is achieving a market share of about 8%. While this is within the range of company expectations, we believe this is probably at the low end of those expectations and would expect to see better in the second phase.

Perhaps most importantly the company has secured additional funding through a recently completed share placing, which raised approximately £1m. This funding will provide working capital and allow the company to develop business in additional markets in Europe and in the Corporate Social Responsibility space. It is also worth noting that KleenAir has agreed to make a £300,000 investment for a 3.85% stake in Nonox plc an unlisted company with IP related to particulate reduction in stationary boilers.

SIGN UP NOW FOR OBJECTIVE'S STOCK RESEARCH - IT'S FREE!

Objective, Independent, Experienced.
Research you can trust!

Yes! Subscribe me for the latest stock research from Objective.
Email address
My Password
My information:
First Name
Family Name
Title:
Job title:
Job function:
Industry:
I am a:
 
To receive occasional printed reports complete your mailing address:
 
Company Name (if any)
Address
 
 
City
Postcode/Zip
Country

Please Read Objective's Terms of Use.


Balkan Resources (Private) - exploring the Perlati copper deposit in Albania
Oct 09, 2009 | Previous Reports

Scancell Holdings (SCLP.PLUS) - differentiated technology and a focused plan offer ingredients for success
Sep 08, 2009 | Previous Reports

Sofame Technologies (SDW.V) - ambitious, but high risk growth strategy
Aug 24, 2009 | Previous Reports

Soho Resources (SOH.V) - substantial upgrade to total resource
Aug 19, 2009 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008 | Previous Reports

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

OCCASIONAL PAPERS

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004

Objective Capital's Contact Information
Partnership, sales and product inquiries: marketing@objectivecapital.co.uk
Media services and conference requests: PR@objectivecapital.co.uk
Subscription and customer service issues: service@objectivecapital.co.uk
Comments or opinions on our analysis: analysis@objectivecapital.co.uk

11-12 Tokenhouse Yard, London EC2R 7AS, United Kingdom
ph +44-(0)870-080 2965 fax +44-(0)870-116 0839

About Us | Contact Us
Latest Analysis | Register Free | Archives
 
Copyright 2004 Objective Capital. All rights reserved.
Terms of Use | Privacy Policy | Disclaimer